The implication of ROCK 2 as a potential senotherapeutic target via the suppression of the harmful effects of the SASP: Do senescent cancer cells really engulf the other cells?

Y. Dilber et al.

Cellular Signalling (2021)

Institution: Gazi University, Turkey

Cell Line: HeLa and A549 (HeLa - cervical cancer cell line; A549 - human lung adenocarcinoma cells)

Research Area: Cell Research

Tags: HoloMonitor M4, cell morphology, Senescent cell secretome, Chemotherapy-induced senescence, Rho/ROCK pathway, Senescence-associated secretory phenotype, Senotherapeutic

Conclusions: Senescence-associated secretory phenotype (SASP) is responsible for chemotherapy adverse effects: drug resistance and the induction of cancer cell proliferation, migration, and invasion. Hence, developing senolytic/semomorphic drugs, targeting senescence cells, are important to improve cancer treatment outcome. In this work, Y. D. Simay with colleagues evaluated if Rho/Rho kinase pathway could be a target for potential drugs in doxorubicin-induced senescent cancer cell lines. Authors have shown that ROCK inhibitors (i.e. ROCK2) have the potential to be developed into semomorphic drugs as they change SASP composition and reduce senescence cell secretory activity. HoloMonitor M4 was used to study cell morphology (cell area, optical volume, and optical thickness).

Read the article …